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Live, attenuated Salmonella Typhimurium vaccine candidate expressing BCSP31,
Omp3b, and SOD proteins of Brucella abortus was constructed. Thirty BALB/c mice
were divided equally into three groups, Group A, were intraperitoneally (IP) inoculated
with 100 µl of approximately 1.2× 106 colony-forming units (CFUs)/ml of the Salmonella
containing vector only in 100 µl as a control. And groups B and C mice were orally and
IP immunized with approximately 1.2 × 109 CFU/ml of the mixture of three delivery
strains in 10 µl and IP immunized with approximately 1.2 × 106 CFU/ml of the mixture
in 100 µl, respectively. The serum IgG, TNF-α and IFN-γ concentrations in groups
B (except Omp3b) and C were significantly higher than those in group A. Following
challenge with B. abortus strain 544; challenge strain was detected <103 CFU from
the spleen of all mice of group C. These results suggest that IP immunization with the
mixture of the vaccine candidate can induce immune responses, and can effectively
protect mice against brucellosis.
Keywords: Brucella abortus, Salmonella Typhimurium delivery system, brucellosis, vaccine
INTRODUCTION
Brucellosis is a zoonotic disease cause infections approximately 500,000 people annually worldwide
(Corbel, 1997; Pappas et al., 2005, 2006; Akhvlediani et al., 2010). The disease remains endemic
in many regions of the world including Latin America, Middle East, Africa, Asia, and the
Mediterranean basin (Pappas et al., 2006). Brucella is predominantly transmitted to humans via
direct contact with fluid discharges from infected animals, but in endemic regions people usually
get infected through the consumption of unpasteurized dairy products mainly goat’s milk and fresh
soft cheese made out of unpasteurized milk (Avila-Calderón et al., 2013).
Brucellosis by Brucella species is facultative intracellular bacteria. Brucella infects domestic
animals, causing abortion and infertility (Godfroid et al., 2005; Avila-Calderón et al., 2013),
however; it can also infect humans producing undulant fever, endocarditis, arthritis and
osteomyelitis (Pappas et al., 2005). Both humoral and cell mediated immunities are necessary to
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change the course of infection of Brucella, but cell mediated
response is crucial for clearance of Brucella from host (Schurig
et al., 2002). Th1 type of immune response mediated by IFN-γ
helps in clearance of Brucella infection (Zhan et al., 1993).
Therefore, live and attenuated strains such as Brucella abortus
strain 19, B. abortus RB51, Brucella melitensis Rev. 1 and
Brucella suis strain 2 have been used to control brucellosis in
domestic animals (Cheville et al., 1993; Deqiu et al., 2002; Blaco,
2010; Avila-Calderón et al., 2013; Olsen, 2013). These live and
attenuated strains may contain a risk because of its potential
possibility to revert virulence bacteria (Goel and Bhatnagar,
2012; Avila-Calderón et al., 2013). In addition, these strains can
confuse with the diagnosis of brucellosis in serum (Olsen et al.,
2009; Avila-Calderón et al., 2013; Olsen, 2013). Because of these
limitations, there is necessary for the development of better
vaccines which are safer to use.
Brucella can cause host infections via mucosa and then
the gastrointestinal tract has been known to be one of the
major entrances of infection route of brucellosis (Gorvel et al.,
2009). Therefore, mucosal immunity is needed to prevent this
enteric infection. Oral vaccination can be successful in inducing
levels of protective secretory IgA on the intestinal surface
(Melkebeek et al., 2013), however, gastric digestion of vaccines
before induction of the immune system is a big barrier in the
development of oral vaccines (Melkebeek et al., 2013). Live,
attenuated Salmonella strains have been proposed as an adequate
vector to deliver orally heterologous proteins and its use can
induces protective mucosal immune responses (Branger et al.,
2009; Pathangey et al., 2009; Causey et al., 2010). The essential
bacterial gene [such as aspartate β-semialdehyde dehydrogenase
(asd)]-based balanced-lethal host-vector system has been used to
continue plasmids co-expressing inserted antigens in Salmonella
1asd mutants and to escape the use of antimicrobials as
marker (Cloeckaert et al., 2002; Hur and Lee, 2011b; Olsen,
2013).
Recombinant proteins are a valuable choice for vaccine and
can induce antigen specific immune response (Zhao et al., 2009;
Goel and Bhatnagar, 2012). An extensively purified protein
from Strain 19, the cell surface 31-kilodalton (kDa) protein (or
BCSP31), can serve as a protective subunit vaccine in rodents
(Tabatabai and Deyoe, 1983; Tabatabai et al., 1989). It has
reported that outer membrane proteins (Omps) can be protective
antigens of the Brucella species (Verstreate et al., 1982). Omp3b,
also known as Omp22, belongs to group 3 of the Brucella
Omps (Vizcaino et al., 2004; Garcia-Yoldi et al., 2005), a highly
conserved family that includes the most immunogenic Brucella
proteins (Cloeckaert et al., 2002). The sodC gene encodes a Cu/Zn
superoxide dismutase (SOD; Bricker et al., 1990; Sriranganathan
et al., 1991). The SOD could function as virulence factor,
since it clears harmful oxy-radicals following phagocytosis by
macrophages (Tabatabai and Pugh, 1994).
The objective of this study was to evaluate immune responses
against B. abortus BCSC31, Omp3b and SOD antigens expressing
by live attenuated Salmonella in a murine model. After
Salmonella delivery strains with BCSP31, Omp3b, and SOD
antigens of B. abortus was constructed, mice were immunized
by various inoculation routes with the delivery strains. Immune
responses induced via intraperitoneal inoculation with the
delivery strains were examined in mice. In addition, we evaluated
the efficacy of the delivery strains for protection against
experimental brucellosis in mice.
MATERIALS AND METHODS
Bacterial Strains and Plasmids
The bacterial strains and plasmids used in present study are
listed in Table 1. Wild-type B. abortus biotype 1 isolated from
cattle was used to amplify gene encoding BCSP31, Omp3b,
and SOD antigens (Table 1). B. abortus strain 544 (strain 544)
was used as the virulent challenge strain (Lee et al., 2014).
The B. abortus biotype 1 isolate was kindly supplied by the
National Veterinary Research and Quarantine Service, Korea.
The attenuated Salmonella Typhimurium (1lon 1cpxR 1asd)
mutant strain, JOL912 (Hur and Lee, 2011a) was used as a host for
delivery of individual antigens. The pMMP65 plasmid was used
as a vector for the expression/secretion of heterologous antigens
in the delivery host (Hur and Lee, 2011a). B. abortus isolate and
strain 544 were grown in Brucella agar (Becton, Dickinson and
Company, Sparks, MD, USA). JOL912 was cultured according to
the method in previous studies (Kang et al., 2002; Hur and Lee,
2011a,b).
Cloning for Recombinant BCSP31,
Omp3b, and SOD Proteins
BCSP31, Omp3b, and SOD proteins were prepared from
HJL206, HJL204, and HJL208, respectively (Table 1), and were
used as coating antigens in enzyme-linked immunosorbent
assay (ELISA). In addition, these antigens were used as
splenocyte stimulating antigens for cytokines concentration
measurement. Briefly, genes for BCSP31, Omp3b, and SOD
proteins were amplified by polymerase chain reaction (PCR)




JOL912 S. Typhimurium 1lon1cpxR1asd Hur and Lee, 2011a
HJL229 JOL912 with pMMP65 This study
HJL228 JOL912 with pMMP65-BCSP31 This study
HJL219 JOL912 with pMMP65-Omp3b This study
HJL213 JOL912 with pMMP65-SOD This study
B. abortus
HJL200 B. abortus biotype 1 isolate from caw in
Korea
Lab stock
HJL254 B. abortus strain 544 (ATCC23448) Lee et al., 2014
Plasmids
pET28a IPTG-inducible expression vector; Kmr Novagen
pET32a IPTG-inducible expression vector; Ampr Novagen
pMMP65 Asd+, pBR ori, β-lactamase signal
sequence-based periplasmic secretion
plasmid, 6x His tag
Hur and Lee, 2011a
Frontiers in Microbiology | www.frontiersin.org 2 April 2016 | Volume 7 | Article 550
fmicb-07-00550 April 18, 2016 Time: 12:53 # 3
Kim et al. Salmonella-based Vaccine Expressing Recombinant Proteins
using specific primer pairs described in Table 2. The amplified
PCR fragments for each gene were digested with restriction
enzymes. Subsequently, the digested fragments were inserted into
commercial expression vectors such as pET28a or pET32a. And
then these plasmids were transformed into Escherichia coli BL21
in order to create HJL206, HJL204, and HJL208 strains. The
recombinant BCSP31, Omp3b, and SOD proteins were prepared
using an affinity purification process with nickel-nitrilotriacetic
acid-agarose (Qiagen, Valencia, CA, USA) from HJL206, HJL204,
and HJL208 respectively. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) was used for the confirmation
of the integrity of purified antigens. All purified antigens were
stored at−70◦C until use.
Preparation of Salmonella Delivery
Strains
The delivery strains were prepared as previously described
with a slight modification (Hur and Lee, 2011a). The genes
for BCSP31, Omp3b, and SOD proteins were prepared by
digestion with restriction enzymes from HJL206, HJL204, and
HJL208 strains, respectively. And then each gene was inserted in
pMMP65 for the construction of vaccine strains. Subsequently,
these plasmids were electroporated into JOL912 to create
HJL228 for BCSP31, HJL219 for Omp3b and HJL213 for
SOD.
Western Blot Analysis
Western blot analysis was carried out to check the secretions
of the individual BCSP31, Omp3b, and SOD proteins from
HJL228, HJL219, and HJL213, respectively, using the modified
method mentioned in previous study (Hur and Lee, 2011a).
Briefly, the proteins in supernatant of culture were separated
by 12% SDS-PAGE gel and transferred onto polyvinylidene
fluoride membranes (Millipore, Billerica, MA, USA). The
individual proteins were reacted with anti-His antibodies
(Invitrogen, Grand Island, NY, USA) and horseradish
peroxidase-conjugated rabbit anti-mouse IgG antibodies
(Southern Biotech., Birmingham, AL, USA). Immunoreactive
bands were detected by addition of the AmershamTM ECL
Prime Western Blotting Detection Reagent (GE Healthcare,
Little Chalfont, Buckinghamshire, UK) and the CheBi
illumination system (Neo science, Suwon, Gyeonggi, South
Korea).
Immunization of Mice and Sample
Collection
Thirty 5-weeks-old female BALB/c mice were equally distributed
into three groups (n = 10 mice per group). All mice were
immunized at 6-weeks-old. Group A mice were intraperitoneally
(IP) inoculated with approximately 1.2 × 106 colony-forming
units (CFUs)/ml of the Salmonella containing vector only
(JHL229) in 100 µl as a control. Group B mice were orally
immunized with approximately 1.2× 109 CFU/ml of the mixture
of the three delivery strains in 10 µl. And group C mice
were IP immunized with approximately 1.2 × 106 CFU/ml
of the mixture of the three delivery strains in 100 µl. Blood
samples were collected before immunization [0 week post-
immunization (WPI)] and again at the third WPI for the
evaluation of serum IgG. All serum samples were stored at−20◦C
until use. The animal experiments mentioned in this study
were performed under ethics approval (CBU 2015-052) from
the Chonbuk National University Animal Ethics Committee in
accordance with the guidelines of the Korean Council on Animal
Care.
Immune Response Measurement by
Enzyme-Linked Immunosorbent Assay
(ELISA)
A standard ELISA was carried out to evaluate the immune
response against BCSP31, Omp3b, and SOD antigens in serum
samples of mice according to the modified method of the
previous study (Hur and Lee, 2011b). Results of the ELISA are
expressed as the mean optical density (OD)± standard deviation.
Cytokine Quantitation of Splenocytes
At 3 WPI, five mice from each group were sacrificed and spleens
were aseptically removed. Splenocytes were prepared according
to the method described in previous study (Adone et al., 2012).
Splenocytes were distributed in 24 well tissue culture plates
with 2 × 106 cells per well (Velikovsky et al., 2003; Cloeckaert
et al., 2004). Splenocytes were stimulated in vitro with each
BCSP31, Omp3b, and SODC antigen (4 µg/well), Concavalin
A (0.5 µg/well) as positive control or media as unstimulated
control, and incubated at 37◦C, 5% CO2 and 95% humidity
(Adone et al., 2012). The supernatants of reaction were collected
after 72 h of re-stimulation and used for cytokine measurement
(Adone et al., 2012).
TABLE 2 | Polymerase chain reaction (PCR) primers used in this study and their product sizes.
Primer Sequence Size (bp) Enzyme site Reference
BCSP31 BCSP31-F CCGCGAATTCCAGGCCCCGACATTTTTCCG 902 EcoRI This study
BCSP31-R CCGCAAGCTTGGATTATTTCAGCACGCCCGC HindIII
Omp3b Omp3b-F CCGCGAATTCGCCGACATGATGGGAGGGAC 563 EcoRI This study
Omp3b-R CCGCAAGCTTACTAGAATTTGTAGTTCAGGCC HindIII
SOD SOD-F CCGCGAATTCAAGTCCTTATTTATTGCATCG 519 EcoRI This study
SOD-R CCGCAAGCTTTTATTCGATCACGCCGCAGG HindIII
Underlines indicate the sites of restriction enzymes.
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Cytokines Measurement by ELISA
The concentration of cytokines such as IFN-γ and TNF-α in
the supernatants was evaluated by the mouse cytokine ELISA
Ready-SET-GO reagent set according to the instructions of
manufacturer (eBioscience, Inc., San Diego, CA, USA).
Challenge Experiments
For challenge experiments, the challenge strain, strain 544 was
prepared. Briefly, the strain was cultured in Brucella broth at
37◦C for 24 h. and resuspended to approximately 1 × 105
CFU/ml. All mice were IP challenged at 3 WPI with 100 µl of the
challenge strain. The spleen weights from all mice were measured
and were diluted as 1:100 using Brucella broth. A total of 100µl of
the diluted media was spread on blood agar to count the number
of viable strain 544 from the spleens at 2 weeks after the challenge.
If no colony detected on the blood agar, means the number of
viable challenge strains from the spleen of mice is <103 CFU.
The vaccine and challenge strains were confirmed by PCR using
B. abortus-specific primer (GAC GAA CGG AAT TTT TCC AAT
CCC), RB51/2308 primer (CCC CGG AAG ATA TGC TTC GAT
CC) and IS711-specific primer (TGC CGA TCA CTT AAG GGC
CTT CAT) in enhanced Brucella AMOS PCR primers (Bricker
and Halling, 1994, 1995).
Statistical Analysis
The number of viable strain 544 from the spleens were
normalized by log transformation and estimated by one-way
analysis of variance, followed by Tukey’s Multiple Comparison
Test using GraphPad program (InStat; GraphPad, La Jolla,
CA, USA). The antibody and cellular immune responses were
compared between the groups by Kruskal–Wallis test and one-
way analysis of variance, respectively using SPSS version 16.0
software (SPSS, Chicago, IL, USA).
RESULTS
Secretion of Recombinant BCSP31,
Omp3b, and SOD Antigens from Vaccine
Candidates
To express the recombinant BCSP31, Omp3b, and SOD
proteins from Salmonella, the proteins encoding genes were
individually cloned into pMMP65 and were transformed into a
MlonMcpxRMasd S. Typhimurium strain. Western blot analysis
was carried out to confirm the secretion of BCSP31, Omp3b and
SOD proteins from the culture supernatants of the constructs.
The expected sizes, 31 kDa for BCSP31, 22 kDa for Omp3b
and 19 kDa for SOD, were observed from the precipitated
supernatants of culture the individual constructs (Figure 1).
Humoral Immune Responses of the
Vaccinated Mice
Antibody responses against each antigen in the serum samples
are presented in (Figure 2). Serum IgG titers against all antigens
in groups B (except Omp3b) and C were significantly increased
compared to those of control group (P≤ 0.05). In addition, serum
FIGURE 1 | Identification of recombinant BCSP31, Omp3b, and SOD
proteins secreted from attenuated Salmonella Typhimurium delivery
system using Western blot analysis. Lanes: BCSP31, recombinant
BCSP31 antigen secreted by JHL228; OMP3b, recombinant Omp3b antigen
secreted by JHL219; and SOD, recombinant SOD antigen secreted by
HJL213.
IgG titers against all antigens in group C than group B were
significantly higher (P ≤ 0.05).
Cytokine Analysis
The TNF-α and IFN-γ concentrations against BCSP31, Omp3b,
and SOD antigens in splenocytes re-stimulated with each antigen
of mice were measured using ELISA on 3 WPI. The levels of
TNF-α and IFN-γ (except Omp3b in group B) were significantly
elevated in the groups B and C than group A (P< 0.05; Figure 3).
Protection against Challenge
All mice were IP challenged with approximately 1 × 104 CFU
of the challenge strain at 3 WPI. The level of protection was
evaluated by the number of viable strain 544 from the spleens at
14 days after the challenge. As shown in (Table 3), groups B and
C mice induced a significantly higher degree of protection than
group A. In addition, a significantly higher degree of protection
was observed in group C mice than group B mice. Furthermore,
among five mice of groups A and B, the challenge strain was
isolated from all mice. However, colony was not detected on
blood agars spread with broth diluting the spleens of all mice of
group C. It means that the number of viable strain 544 from the
spleen of group C mice is<103 CFU.
DISCUSSION
The small intestine is a major site of nutrient digestion and
absorption (Moreto and Perez-Bosque, 2009). In addition, the
intestinal epithelium plays a crucial role in the prevention
of pathogenic microorganisms entering the interior space of
animals (Moreto and Perez-Bosque, 2009). B. abortus can invade
hosts through mucosa and is a facultative intracellular bacterium
that survives inside phagocytes by escaping the endocytic
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FIGURE 2 | Serum IgG titers against BCSP31, Omp3b, and SOD antigens. Group A mice were intraperitoneally (IP) inoculated with approximately 1.2 × 106
CFU/ml of the Salmonella containing vector only in 100 µl as a control, group B mice were orally immunized with approximately 1.2 × 109 CFU/ml of the mixture of
the three delivery strains in 10 µl and group C mice were IP inoculated approximately 1.2 × 106 CFU/ml of the mixture of the three strains in 100 µl. Data are the
mean optical density (OD) of all mice in each group, and error bars show the standard deviations (SD). Asterisks indicate a significant difference between the titers of
the immunized group and those of the control group (∗P < 0.05).
pathway (Godfroid et al., 2005; Baldwin and Goenka, 2006;
Avila-Calderón et al., 2013). The gastrointestinal tract has been
known to be one of the major portals of B. abortus infection
(Gorvel et al., 2009). Therefore, the host resistance to Brucella
infections depends mainly on mucosal immunity and cell-
mediated immunity (Baldwin and Parent, 2002; Paranavitana
et al., 2005). Live attenuated Brucella vaccines that can stimulate
strong mucosal and cell-mediated immune responses are usually
very effective against brucellosis (Bricker and Halling, 1994;
Murphy et al., 2001; Baldwin and Goenka, 2006). However,
live vaccines induce antibodies that confuse the diagnosis of
field infection in vaccinated animals (Olsen et al., 2009; Avila-
Calderón et al., 2013; Olsen, 2013), which further hinder
brucellosis eradication (Velikovsky et al., 2003; Cloeckaert et al.,
2004; Izadjoo et al., 2004). In addition, vaccination of pregnant
cows with some live vaccine may induce low level abortion
or premature birth. Thus it is recommended to be used with
caution in pregnant cattle (Olsen et al., 2009; Lin and He, 2012;
Avila-Calderón et al., 2013).
In previous studies (Chen and Schifferli, 2003; Hur and Lee,
2011a; Hur et al., 2011, 2014) live attenuatted Salmonella, a
facultative intracellular bacterium, has been known to induce
a strong mucosal immune response as well as cell-mediated
immune response. In addition, live attenuated Salmonella, as
a vector to transfer heterologous proteins, has many benefits
such as delivering the protein to the host, and easy preparation
and handy inoculation (Chen and Schifferli, 2003; Hur et al.,
2011). Especially, oral immunization with live attenuated
Salmonella vaccine expressing the recombinant rBL protein
induced significant protective effect, although this protection
was lower than that by the inoculation with the pBL DNA
vaccine (Zhao et al., 2009). Major Omps of Brucella species
TABLE 3 | Bacterial proliferations in spleen of mice challenged with a
wild-type B. abortus strain 544.
Group Log10CFU/spleen (mean ± SD) Significance (P)
A 4.36 ± 0.21
B 3.48 ± 0.17 <0.05
C <3.0 ± 0.0 <0.05
Groups A–C values refer to Figure 2.
FIGURE 3 | Cytokine concentrations in the splenocytes at 3 weeks post-immunization. Groups A–C refer to Figure 2. Data are the mean of all mice in each
group; error bars show SD. Asterisks indicate a significant difference between the values of each group mice (∗P < 0.05).
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have been known to be immunogenic antigens for effective
protection against brucellosis (Cloeckaert et al., 2002). In present
study, we conducted a new Brucella vaccine candidate, attenuated
Salmonella strain expressing Omps of Brucella. We analyzed the
immunogenicity and protective efficacy of the vaccine strains
against virulent Brucella infection in BALB/c mice immunized
via various routes with the candidate. BALB/c mouse has been
known to be a proven animal model to study the protection of
Brucella vaccine candidates (Jain et al., 2014).
In the present study, the attenuated S. Typhimurium 1lon
1cpxR 1asd strain and the pBP65 plasmid encoding the asd
gene (Hur et al., 2011) was used as a delivery system to deliver
BCSP31, Omp3b and SOD proteins of B. abortus. Secretion of
each antigen from the vaccine candidate was demonstrated by
Western blot analysis. This results indicated that the plasmids
carrying the genes for BCSP31, Omp3b, and SOD proteins
were stably maintained in the vaccine candidates, and that
the recombinant BCSP31, Omp3b, and SOD proteins were
effectively expressed and secreted. This combination of three
S. Typhimurium strains expressing each other protein were
determined from preliminary experiments to determine optimal
union among various combinations using S. Typhimurium
strains expressing each protein, such as BCSP31, Omp3b,
Omp10, Omp25, SOD. Two different immunization routes of
mice, such as oral (group B) and IP (group C), were used to
evaluate the immunogenicity and limitation of colonization of
B. abortus strain 544 in spleen. The mice of groups B (except
Omp3b) and C induced significant higher amounts of serum IgG
titers to BCSP31, Omp3b, and SOD antigens than mice of control
group A. These results show that immunization with the vaccine
candidate irrespective of inoculation routes can induce systemic
immune response.
Brucella abortus is a facultative intracellular bacterium.
Therefore, cell-mediated immune response is necessary for
clearance of the bacteria (Baldwin and Parent, 2002; Paranavitana
et al., 2005). Especially, Th1 type immune response is considered
as necessary to protect completely brucellosis (Zhan et al., 1996;
Murphy et al., 2001; Baldwin and Goenka, 2006). The role of
TNF-α to limit colonization of B. abortus in spleen of mice
has been known to be critical for activation of macrophages
to kill B. abortus in the absence of IFN- γ (Zhan et al., 1996;
Murphy et al., 2001). IFN- γ plays a critical role in the clearance
of B. abortus by its ability to activate antibacterial functions of
infected macrophages (Paranavitana et al., 2005; Baldwin and
Goenka, 2006). We studied the cell mediated immune response
generated by various immunization routes with the vaccine
candidates expressing BSCP31, Omp3b, and SOD antigens of
B. abortus. TNF-α and IFN-γ concentrations were evaluated
from the supernatants of the re-stimulated splenocytes following
restimulation of splenocytes with heat-inactivated B. abortus
whole antigens of mice immunized with the vaccine candidates.
TNF-α and IFN-γ (except Omp3b in group B) concentrations
were significantly higher in groups B and C mice than in group A
mice. These results indicate that immunization with the conducts
irrespective of inoculation routes may induce strong Th1 type
immune responses. Furthermore, significantly high levels of IFN-
γ as well as TNF-α in splenocyte culture supernatants relative
to group B could be observed in group C. It seems logical to
conclude that TNF-α and IFN- γ produced by IP immunization
with the candidate can have been associated with the increased
protection.
The lack of well-established correlation of protection against
Brucella is a critical difficulty of a novel vaccine candidate
(Zhao et al., 2009). In previous study, oral immunization
group with live attenuated Salmonella vaccine expressing the
recombinant fusion protein rBL induced significant protection
than control group after oral inoculation with B. abortus strain
544 (Zhao et al., 2009). However, the results only showed that
the mice immunized with live attenuated Salmonella vaccine
expressing the recombinant fusion protein could decreased the
number of colonization of Brucella in spleen (Zhao et al.,
2009). Similarly, groups B and C mice relative to group A
mice significantly limited colonization of B. abortus strain 544
in spleen. These results show that immunization with the
candidates irrespective of inoculation routes can protect mice
from virulent B. abortus strain 544 infection. Furthermore,
in this study, group C mice showed the best protection
against virulent B. abortus strain 544 infection. The reason
could be that IP immunization with the candidate coffered
large amounts of antigens into antigen-presenting cells, which
induced the strongest mucosal and cell-mediated immune
responses.
CONCLUSION
The results of this study show that immunization with the
Salmonella delivery system based Brucella vaccine induces
robust mucosal and cell mediated immune response in mice.
Immunization with the vaccine candidate irrespective of
inoculation routes confers protection against B. abortus infection.
Furthermore, in this study, mice IP immunized with the vaccine
candidate showed the best protection against B. abortus strain
544 infections. On theses bases, we believe that IP immunization
with the vaccine candidate can effectively protect brucellosis.
In addition, these results imply that combination of live,
attenuated Salmonella Typhi strains expressing each antigen such
as BCSP31, Omp3b, and SOD, may attempt to study as vaccine
candidate against human brucellosis, if the attenuated strains
should prove safe use in human.
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